KALA BIO, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
Mailing Address 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
Phone 781-996-5252
Fiscal Year End 1231
EIN 270604595
Financial Overview
FY2024
$12.33M
Stockholders' Equity
$51.18M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | February 10, 2026 | View on SEC |
| 3 Initial insider ownership report | February 9, 2026 | View on SEC |
| 3 Initial insider ownership report | February 9, 2026 | View on SEC |
| 3 Initial insider ownership report | February 9, 2026 | View on SEC |
| 3 Initial insider ownership report | February 9, 2026 | View on SEC |
| 3 Initial insider ownership report | February 9, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | February 6, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
Material Events
8-K Leadership Change February 5, 2026
High Impact
- Avi Minkowitz, with strong background in financing, M&A, and restructuring, appointed as new CEO and CFO.
- Potential for renewed focus on financial health, fundraising, cost management, and strategic deals.
8-K Financial Distress January 23, 2026
High Impact
- KALA BIO received a Nasdaq delisting warning for non-compliance with the $1.00 minimum bid price rule.
- The company has until July 20, 2026, to regain compliance by achieving a $1.00 closing bid price for ten consecutive business days.
8-K Financial Distress January 6, 2026
High Impact
- KALA BIO issued a total of 4.6 million new shares of its common stock.
- The shares were used to settle various debts and obligations, including payments to advisors, a marketing firm, a major investor, and employees, thereby conserving cash.
8-K Financial Distress January 2, 2026
High Impact
- KALA BIO, Inc. settled a $10.6 million debt with Oxford Finance, LLC for a payment of $2 million.
- This settlement significantly improves KALA BIO's financial health by removing a substantial debt from its books.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.